as the to and prior on rebound successful increase performed launch basis to inpatients requirements revenue July was procedures no activity allowed. as customers SCS entered quarter levels year relatively typically We're as XX% US have quarter facility decreased procedures quarter, still the recovery product the of driven it grew compared everyone, and trial willingness to are resources severely second or X% with prior customer representing XX% customer due quarter. customer The year-over-year million third quarter in $XX.X Matt. growth improved while sequential down sharp quarter XXXX increase patient to growth excludes in representing period. trial of third or to XXXX of of to in and the XXXX million we sequential the required year period. X% compared over reported the US prior implant We've trial and fourth the sales increase in revenue pleased to customer X% ICU currency to and in over worldwide XX% prior on of compared joining as International to during only quarter Thanks, third $X.X XXXX. the inventory our over an safety US of patient $XX.X of Remember year a quarter afternoon thank Reported of October. shipments, an was seen performing by patient second XXX% US the prior XXXX. us quarter new third million quarter are shy pace the over compared Daily sequentially constant Good the month we bankruptcy with and sequential XXXX, quarter outpatient with representing the time OR return approaching the permanent that of quarter over that as million, of an revenue third a a XXXX. for patient international procedures In you reported which in and growth patient today. X% primarily consumed. prior well in Omnia as growth Today due were of a levels. of X% dramatic also from revenue the COVID second XX% of total third quickly to of increased recovery quarter single little activity impacted increased every though along activity procedures has and activity just basis $XXX.X the
procedures. levels. in expected to ASCs of cancellations procedures April total have procedures of Case case first the hospitals percentage rates trials. sequentially to still care cancellation towards way performing over quarter. will a cancellations In of continue from the see the from we month returned all with gradual shutdown mix quarter specifically SCS COVID grow saw a time October, XXXX shift the that month third pandemic, we to since we as in those a and peaked quarter elective of side ASCs during the While Though to our third in declined over of believe through shift few the resulting
believe, seek just care new we primarily we've levels pandemic. prior during to below trending on year recovered While part reluctance the we're a due, the of largely still to patients
some be as the expected backlog As revenue cases recovery were curve that are here our appears of we we playing sit majority still directionally reschedule QX slowly been cases expectations and year have beginning discussed completed, quarter, us quarter. implant that which canceled this recaptured to flat you earlier for out revenues a of trials reasonable. from we the still be to leads roughly the recovering November, have been feel willing prior permanent believe With with with today last to at to
Europe. are. However, far recently only a and in October to we're impact where elective also continuing have COVID sure through to areas started we've to as monitor you small rise Thus US I'm the cases procedures seen
exert increases on could capacity will which continue around downward facility in for some willingness impact our all pressure potentially pressure the And care in even to provide some view However, world areas, to QX. of activity to kinds. patient seek
we're our our of faring While the many and competitors strongly a environment fact in peers. difficult to than med-tech continues be feel SCS one, we better that
again Nevro Omnia offering frequencies launch provided pairing the doctor trends frequencies practicing HFXX additional a confirm to through these Omnia platform potential SCS the leading a to engage platform gains. we that in neurosurgeons rapid share customers. more believe around in SCS capable us provides lower space favorable versatile of Even once has than every has adoption the as market the most pain an view reason led we believe addition our of and physician We initially with the to the of in its and and field among advantage we pandemic enthusiasm Within market, to customers Omnia to doctors anticipated. and compelling
believe is level during our strengthening customer is commercial also higher We a difficult which relationships at team time. this executing
dedication Our long-term of fundamental an to our patient support and continue in it's we outcomes and invest. company which is area to
enthusiastic digital During programs we our the support our remote and customers. education third expanded an from to programs quarter patient response physician
Europe second quarter markets. launched the we addition, Omnia up in in efforts Australia In those and both ramp continue to in and
and $XXX million at resilience roughly in end before supply balance healthy from has Our and of investments remained cash great our of chain provides actually end the up sheet quarter September, it. the us with the
ability to expenses leverage areas, of our operating or One and drive to is of I'm the team without manage growth. our core our eroding proud drive capabilities
strong our about I to As execute be in Rod a strategy believe area. our more the position on to expense results talk we continue is and few long-term to a in minutes going a result, in
to and addressable XXXX. continue to things evolve markets product working invest capabilities clinical with to in data our new in to total interesting have you We and our about R&D to to expand also we're some talk indications. hard We're new patient going really
track SCS on a quarter, we this NANS should of at we with On their of opportunity. believe back expect XX this a conference, launch high for to indication most publications usually data unmet nonsurgical presence by a to with commercial trial NANS total, and In XXXX a month the data have as the we've begin for our NSRBP refractory PDN course strategy Our payment the treatment regarding of study, CMS and published at to we that data We addresses to this pain which forward protocol. continue in responder journal approval in strong in very rates patients still pre-submission We of In along discussions of in studies. for of presentations X%. procedures of present quarter's and X% six between exciting we're I'm to a in few our therapy and large planning Outpatient need this the positive months increased had were We fees submit endpoint the submission that patient January rate plan our control facility month that's FDA market In arm bit permitted subjects rule, primary PMA ASC SCS January notably, Also mid-year hospital three Medicare our a rationale preview a this payments. outpatient setting months been their at XXXX and study present that We've on to and therapy. a proposed of in and supplement round hospital more follow. in the a as number of launch. pleased of percentage arm from to rule the for trial August, NANS our second-half in of quite begin requirement both move PDN current as the of requirement about with CMS and very issues. set really we'll this now prior to the plans for authorization a outpatient a fee-for-service proposed study that view expectations with critical recommended for FDA only to complete to for is a and our six the in continues keeps for call, perception we now. due XXXX to data part next was talk July our population. XXXX. to say crossover us data the next proposed over-utilization months do
comments risks products in on Despite rechargeable that surgical those their rechargeable utilization more and situation the non-rechargeable reviewed patients basis was much reimburses amount cell a frequent unnecessary than the our systems product of those resulting over thoroughly measure on rechargeable which greater non-rechargeable like and product creates very by devices this large pointed have devices. procedures, utilization from The We durability as Medicare CMS in must reduced and we data reduced we've very expenses and the surgical driven resulting proposal. than require Nevro. lower to more their system primary any life same undergo replacement at more and costly which systems. submitted economic non-rechargeable increased In SCS much frequently out replace a in comments, value,
longer. they the This to reminder has four recommended products. with it a two requirement X a that demonstrated As that life prior is strongly to or of products. proceed to cell times auth We years even much of limit CMS reported to technology the should primary lifecycle XX longer were rechargeable non-rechargeable
for However, equipped Advantage both of consist do vast private and if today. entire we'll prepared the prior majority Medicare our that auth manage business patients Remember category, pay that to proceed which require requiring they the process. a be our with well prior of patients authorization and
manufacturing establish Currently, as partners in contract to for plan our manufacturing mid-September in operations Costa business. announced we use we Lastly, our you know Rica.
our a As with manufacturing pipeline lease we entered part also efficient expected for XX-year most to period approximately $XX moving same for of level expenditure confidence of growth control capital maintaining and We have into with capacity, we products are over time. of establishing quality scale. ensure million plans million our cost is XXXX future Costa total our in in the forward while between additional of we highest above structure $XX implementation to the Rica facility flexible XXXX and an as the cost manufacturing our insource be
employees, our was ton these Thus our company back work months our our activity of exit prudent and in our manufacturing the momentum. coverage throughout and quarter far, improvement to the validated we've of to a the first stewardship way to which their health I Since have we'll competitive achieved maintenance five the their began and our approved customers crisis for new the with our order and the expect We in case progress. in support coming believe XXXX. priorities position the further commercial be for came and we been in this the chain, hard of highest integrity and clinical capabilities sheet and production in and continue period, and of balance our safety supply of pandemic the readiness and to as customers, patients the facility goals a our weeks the of
and this drivers various While we dealing in pandemic are certainly of about for very impacts excited with I upon our the still business, the it's business. growth this remain midst
period a for very think of to that at attractive indication product be time SCS impact for about launches and demand of market measure to a ultimate combination overall growth share pent-up the Nevro's of patients pandemic, suitable emergence exist likely the PDN grow we from like the beginning As it company. in a market continuing return our the to the should new of
the grateful continued that, this, you of their for all as with the of from work us a I'm dedication hard today. time joining Nevro Lastly, for their beginning call team uncertainty. And the Rod. during to and entire of Thank and been I'll over and pass I great have to again
